[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-light-chain-amyloidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-light-chain-amyloidosis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100595986","phase-2-study-evaluating-the-efficacy-and-safety-of-cm336-injection-in-the-treatment-of-light-chain-amyloidosis-100595986",false,"NCT07039578","Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis","An Open-Label, Multi-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Relapsed or Refractory Primary Light-Chain Amyloidosis","Inclusion Criteria:\n\n* Voluntary provision of written informed consent and ability to comply with protocol requirements.\n* Age ≥18 years, any gender.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.\n* Confirmed diagnosis of primary light-chain (AL) amyloidosis.\n* Relapsed or refractory primary AL amyloidosis.\n* Measurable hematologic disease at screening (per protocol-defined criteria).\n* Involvement of ≥1 amyloid-affected organ.\n* Adequate organ function meeting all protocol-specified criteria within 3 days prior to first dose.\n\nExclusion Criteria:\n\n* Current or prior diagnosis of multiple myeloma.\n* Received anti-AL amyloidosis therapy within protocol-specified timeframe prior to first dose.\n* Clinically significant cardiovascular or cerebrovascular disease.\n* Any active or uncontrolled infection meeting protocol-defined criteria.\n* Any other condition deemed by the Investigator to preclude safe study participation.","ALL","18 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","to Evaluate the Efficacy and Safety of CM336 (BCMA\u002FCD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis",[26],"Primary Light-Chain Amyloidosis","RECRUITING","2025-11-20",{"date":30,"type":31},"2025-11-26","ACTUAL",{"date":33,"type":31},"2025-07-25",{"date":35,"type":20},"2029-07-31",{"name":37,"class":38},"Keymed Biosciences Co.Ltd","INDUSTRY",2]